COMMUNIQUÉS West-GlobeNewswire

Cytosurge annonce une transition stratégique de sa direction

10/01/2025 - 15:32

Simon Egli est nommé directeur général tandis que Pascal Behr, cofondateur, devient membre du conseil d’administration ZURICH, Suisse, 10 janv. 2025 (GLOBE NEWSWIRE) -- Cytosurge AG, leader de la manipulation [...]

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

10/01/2025 - 15:26

Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data from GD2-SADA Phase [...]

Les détecteurs Focus HD et le système de radiologie mobile DRX-Rise de Carestream reçoivent l’autorisation de marquage CE par l’Union européenne

10/01/2025 - 15:11

ROCHESTER, New York, 10 janv. 2025 (GLOBE NEWSWIRE) -- Carestream Health a annoncé ce jour avoir reçu l’autorisation de marquage CE de l’Union européenne pour ses détecteurs Focus HD et son système de radiologie mobile [...]

HMNC Brain Health Completes Patient Randomization for Phase 2b OLIVE Trial for Major Depressive Disorder

10/01/2025 - 15:02

Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related Depression MUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC”), a clinical-stage precision psychiatry biopharma company pioneering [...]

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

10/01/2025 - 15:00

This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and [...]

Disc Medicine Highlights Recent Achievements Across Hematology Portfolio and Key Business Objectives and Milestones for 2025

10/01/2025 - 15:00

In Q1 2025, the Company will discuss the plans for NDA submission under a potential accelerated approval path for bitopertin in erythropoietic protoporphyria (EPP), following a Type C meeting with FDA on confirmatory [...]

ADARx Pharmaceuticals to Present at the J.P. Morgan 43ʳᵈ Annual Healthcare Conference

10/01/2025 - 15:00

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, [...]

Windward Bio Launches With $200 Million Series A Financing to Develop Phase 2-Ready, Long-Acting Anti-TSLP Antibody With Best-in-Class Potential in Asthma and COPD

10/01/2025 - 14:45

Highly experienced management team with a successful track record in advancing compounds from target identification to commercialization Top-tier global investors fund the company through clinical proof of concept of [...]

OneMedNet Regains Compliance with NASDAQ Minimum Bid Price Requirements

10/01/2025 - 14:45

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World [...]

Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations

10/01/2025 - 14:38

SCOTTSDALE, Ariz., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, announced today new partnerships with [...]

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

10/01/2025 - 14:30

New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a [...]

IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

10/01/2025 - 14:30

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 million Reports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 million [...]

TOMI Environmental Solutions Positioned to Address Growing Global Disease Threats with SteraMist Technology

10/01/2025 - 14:30

Company Expands Reach to Government, Commercial Entities, and School Districts Amid Rising Concerns Over Spread of Respiratory Viruses such as RSV, HMPV, and H5N1 FREDERICK, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- TOMI [...]

NeuroOne® Announces Preliminary Unaudited First Quarter Fiscal 2025 Revenue Increase to a Record $6.2 Million

10/01/2025 - 14:30

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a [...]

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

10/01/2025 - 14:30

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies [...]

InflammX Therapeutics Announces Option Agreement with Bausch + Lomb

10/01/2025 - 14:30

TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- InflammX Therapeutics Inc., a clinical-stage biotechnology company focused on developing innovative therapies for retinal diseases with significant unmet needs, announced [...]

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

10/01/2025 - 14:30

Marks a step forward in b roadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) , atypical hemolytic uremic syndrome ( aHUS ) and generalized myasthenia gravis ( gMG ) in the U . S . P [...]

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

10/01/2025 - 14:23

LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody ® First-in-human study enrolling adult patients with CD123-expressing AML or MDS Initial Phase 1 data read-out expected by year-end 2025 UTRECHT, The [...]

OrthoPediatrics Corp. Announces Expansion of Specialty Bracing Division

10/01/2025 - 14:05

WARSAW, Ind., Jan. 10, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]